FYREMADEL

This brand name is authorized in Spain, Finland, France, Malta, Netherlands, Poland, United Kingdom

Active ingredients

The drug FYREMADEL contains one active pharmaceutical ingredient (API):

1 Ganirelix UNII 56U7906FQW - GANIRELIX ACETATE

Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the GnRH receptors in the pituitary gland. As a result a rapid, profound, reversible suppression of endogenous gonadotrophins occurs, without initial stimulation as induced by GnRH agonists. Read about Ganirelix

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
FYREMADEL Solution for injection in pre-filled syringe	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H01CC01	Ganirelix	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CC Anti-gonadotropin-releasing hormones
Discover more medicines within H01CC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 78205
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 409293, 551779
Country: FR	Base de données publique des médicaments	Identifier(s): 61462270
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 349001, 349002
Country: MT	Medicines Authority	Identifier(s): AA770/16301
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 59048
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100438472